Grifols (GRFS) Accounts Payables (2009 - 2025)
Grifols' (GRFS) quarterly Accounts Payables came in at $979.0 million in Q4 2025, down 18.42% YoY from $1.2 billion in Q4 2024, and down 18.42% on a QoQ basis from $1.2 billion in Q4 2024.
Grifols (GRFS) Accounts Payables (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Accounts Payables data on file, last reported at $979.0 million in Q4 2025.
- Quarterly Accounts Payables fell 18.42% year-over-year to $979.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $979.0 million (down 18.42% YoY) and the FY2025 annual result came in at $979.0 million, down 18.42% from the prior year.
- Accounts Payables retreated to $979.0 million in Q4 2025, from $1.2 billion in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.2 billion in Q4 2024 to a low of $803.9 million in Q4 2022.
- A 5-year average of $953.4 million and a median of $898.4 million in 2021 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables jumped 35.53% — and 2025, when it retreated 18.42%.
- Tracing GRFS's Accounts Payables over 5 years: stood at $898.4 million in 2021, then decreased by 10.52% to $803.9 million in 2022, then advanced by 10.14% to $885.4 million in 2023, then surged by 35.53% to $1.2 billion in 2024, then dropped by 18.42% to $979.0 million in 2025.
- The last three Accounts Payables figures came in at $979.0 million (Q4 2025), $1.2 billion (Q4 2024), and $885.4 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.87 Bn | 632.12 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 470.09 Bn | 463.52 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 375.69 Bn | 368.55 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.40 Bn | 295.71 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.51 Bn | 252.61 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 236.27 Bn | 222.28 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.86 Bn | 178.68 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.16 Bn | 101.99 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 1.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 978.96 Mn |
| Dec 31, 2024 | 1.20 Bn |
| Dec 31, 2023 | 885.45 Mn |
| Dec 31, 2022 | 803.92 Mn |
| Dec 31, 2021 | 898.41 Mn |
| Dec 31, 2020 | 717.30 Mn |
| Dec 31, 2019 | 644.08 Mn |
| Dec 31, 2018 | 825.93 Mn |
| Jun 30, 2018 | 509.83 Mn |
| Dec 31, 2017 | 498.17 Mn |
| Jun 30, 2017 | 434.13 Mn |
| Dec 31, 2016 | 660.71 Mn |
| Sep 30, 2016 | 436.40 Mn |
| Jun 30, 2016 | 452.56 Mn |
| Dec 31, 2015 | 449.39 Mn |
| Sep 30, 2015 | 391.32 Mn |
| Jun 30, 2015 | 406,464.33 |
| Mar 31, 2015 | 430.85 Mn |
| Dec 31, 2014 | 549.47 Mn |
| Sep 30, 2014 | 521.73 Mn |